On April 26th TFS International (TFS) completed the acquisition of the New Jersey-based Oncology and Vaccine specialist Contract Research Organization (CRO), Beardsworth Consulting Group, Inc. (BCG).

In a move to expand its oncology and vaccine research services, TFS has announced the completion of acquiring BCG, an independent clinical CRO with headquarters in Flemington, New Jersey, and with clinical research professionals located throughout North America.

The acquisition of BCG follows the TFS global strategy to grow its North American operations to 600 professionals, with comparable capabilities and expertise to its existing European business. The BCG acquisition will complement TFS’ competences in oncology and vaccines, among several other therapeutics areas, as well as provide scalable operational resources throughout North America.

“The BCG deal is really a welcome component in the strategic vision of TFS. It adds competencies in active and growing therapeutic areas, increases our operational capabilities in North America and expands substantially our customer portfolio of smaller and midsized life science companies in one of the most important global research markets. It aligns very well with where we want to be as a company,” said Mr. Daniel Spasic, Chief Executive Officer at TFS.

TFS has recently completed several acquisitions and the BCG deal follows two other transactions in the last five months, including the acquisition of Dimensione Ricerca in Italy and the technology provider for Electronic Data Capture (EDC) services, Semcon in Sweden.